Chong Kun Dang Partners with Synapix for Antibody-Drug Conjugate Advancement

Chong Kun Dang announced that it had signed a contract with Synapix of the Netherlands to introduce ADC (Antibody-drug conjugate) technology on the 6th.

The contract comprises approximately 132 million dollars (KRW 165 billion), including the down payment, development cost, licensing, and sales milestones. And after commercialization, royalties for each stage of sales are assessed separately.

With this contract, Chong Kun Dang plans to secure the right to use Synapix's three antibody-drug conjugate platform technologies, ▲GlycoConnect™, ▲HydraSpace™, and ▲toxSYN™, and commence to develop ADC anticancer drugs aggressively.

Synapix's ADC platform technology is an innovative next-generation technology. It can implement a site-specific conjugation in which a precise number of drugs are conjugated to an antibody at a specific location.

While other technologies require antibody modification, Synapix's technology, which can apply previously discovered antibodies as ADCs without modification, enables efficient, safe production from toxicity and has superior efficacy than existing ADCs.

Chong Kun Dang CEO YoungJoo Kim declared, "Chong Kun Dang is building expertise and know-how through producing various anticancer drugs, including the small cell lung cancer drug 'Camptobel' and the anticancer bispecific antibody CKD-702." "Through this contract with Synapix, we will speed up the development of next-generation anticancer drugs that will lead the global market," he added.

Peter van de Sande, CEO of Synapix, stated, "We are pleased that Synapix's new antibody-drug conjugate technology is included in the pipeline of Chong Kun Dang, which has outstanding capabilities in the field of anticancer drugs." "We plan to continue close and long-term cooperation so that Chong Kun Dang can develop innovative anticancer drugs that patients need in the future," he sounded.